Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BT2 是 BCKDC 激酶(BDK)抑制剂,IC50值为 3.19 μM。它也是一种选择性的Mcl-1抑制剂,Ki 值为 59 μM。BT2 与 BDK 结合触发 N 端结构域的螺旋运动,导致 BDK 从支链 α-酮酸脱氢酶复合物 (BCKDC) 中解离。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 163 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,150 | 现货 | ||
50 mg | ¥ 1,830 | 现货 | ||
100 mg | ¥ 2,720 | 现货 | ||
500 mg | ¥ 6,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 448 | 现货 |
产品描述 | BT2, a BCKDC kinase (BDK) inhibitor, exhibits an IC50 of 3.19 μM and functions as a potent, selective Mcl-1 inhibitor with a Ki value of 59 μM. Its interaction with BDK induces helix movements in the N-terminal domain, leading to BDK's dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). |
靶点活性 | BDK:3.19 μM (IC50), MCL1:59 μM (Ki) |
体内活性 | BT2 treatment reduces the protein levels of BDK in kidneys and heart. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 (20 mg/kg/day; i.p.; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively [1]. |
别名 | 3,6-二氯-2-苯并噻吩羧酸 |
分子量 | 247.1 |
分子式 | C9H4Cl2O2S |
CAS No. | 34576-94-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (337.23 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.0469 mL | 20.2347 mL | 40.4694 mL | 101.1736 mL |
5 mM | 0.8094 mL | 4.0469 mL | 8.0939 mL | 20.2347 mL | |
10 mM | 0.4047 mL | 2.0235 mL | 4.0469 mL | 10.1174 mL | |
20 mM | 0.2023 mL | 1.0117 mL | 2.0235 mL | 5.0587 mL | |
50 mM | 0.0809 mL | 0.4047 mL | 0.8094 mL | 2.0235 mL | |
100 mM | 0.0405 mL | 0.2023 mL | 0.4047 mL | 1.0117 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BT2 34576-94-8 Apoptosis BCL Bcl-2 Family Inhibitor inhibit BT 2 BT-2 3,6-二氯-2-苯并噻吩羧酸 inhibitor